Seach Medical Group Past Earnings Performance
Past criteria checks 0/6
Seach Medical Group's earnings have been declining at an average annual rate of -3.8%, while the Pharmaceuticals industry saw earnings growing at 11.3% annually. Revenues have been growing at an average rate of 41.8% per year.
Key information
-3.8%
Earnings growth rate
-5.0%
EPS growth rate
| Pharmaceuticals Industry Growth | 35.1% |
| Revenue growth rate | 41.8% |
| Return on equity | -13.3% |
| Net Margin | -7.0% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Is Seach Medical Group (TLV:SEMG) A Risky Investment?
Feb 21
Is Seach Medical Group (TLV:SEMG) A Risky Investment?
Oct 12Seach Medical Group (TLV:SEMG) Has Debt But No Earnings; Should You Worry?
Jul 14Seach Medical Group (TLV:SEMG) Has A Pretty Healthy Balance Sheet
Feb 27Seach Medical Group Ltd's (TLV:SEMG) Share Price Not Quite Adding Up
May 13Seach Medical Group's (TLV:SEMG) Shareholders Have More To Worry About Than Lackluster Earnings
Dec 02Declining Stock and Decent Financials: Is The Market Wrong About Seach Medical Group Ltd (TLV:SEMG)?
Mar 18Seach Medical Group's(TLV:SEMG) Share Price Is Down 20% Over The Past Year.
Jan 22Has Seach Medical Group Ltd (TLV:SEMG) Stock's Recent Performance Got Anything to Do With Its Financial Health?
Dec 18
Revenue & Expenses BreakdownBeta
How Seach Medical Group makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 150 | -11 | 38 | 2 |
| 30 Sep 23 | 149 | -5 | 40 | 1 |
| 30 Jun 23 | 142 | -6 | 40 | 1 |
| 31 Mar 23 | 140 | -3 | 37 | 1 |
| 31 Dec 22 | 134 | -3 | 33 | 1 |
| 30 Sep 22 | 125 | 6 | 29 | 2 |
| 30 Jun 22 | 111 | 5 | 24 | 2 |
| 31 Mar 22 | 87 | 3 | 20 | 2 |
| 31 Dec 21 | 67 | 5 | 16 | 2 |
| 30 Sep 21 | 49 | 7 | 12 | 2 |
| 30 Jun 21 | 39 | 10 | 11 | 2 |
| 31 Mar 21 | 40 | 13 | 11 | 2 |
| 31 Dec 20 | 37 | 12 | 11 | 2 |
| 30 Sep 20 | 33 | 10 | 10 | 2 |
| 30 Jun 20 | 35 | -18 | 9 | 2 |
| 31 Mar 20 | 31 | -22 | 9 | 2 |
| 31 Dec 19 | 29 | -23 | 7 | 2 |
| 31 Mar 19 | 20 | 8 | 4 | 1 |
| 31 Dec 18 | 19 | 8 | 3 | 0 |
| 31 Dec 17 | 12 | 3 | 2 | 0 |
| 31 Dec 16 | 9 | 2 | 1 | 0 |
Quality Earnings: SEMG is currently unprofitable.
Growing Profit Margin: SEMG is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: SEMG is unprofitable, and losses have increased over the past 5 years at a rate of 3.8% per year.
Accelerating Growth: Unable to compare SEMG's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: SEMG is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (6.7%).
Return on Equity
High ROE: SEMG has a negative Return on Equity (-13.34%), as it is currently unprofitable.